Interval colorectal cancers after negative faecal immunochemical test in a 13-year screening programme.


Journal

Journal of medical screening
ISSN: 1475-5793
Titre abrégé: J Med Screen
Pays: England
ID NLM: 9433359

Informations de publication

Date de publication:
06 2021
Historique:
pubmed: 13 5 2020
medline: 11 9 2021
entrez: 13 5 2020
Statut: ppublish

Résumé

To assess faecal immunochemical test sensitivity for cancer in a very large population-based cohort followed up for six rounds with biennial faecal immunochemical test repetition. This study is based on interval colorectal cancers diagnosed in a cohort of subjects aged 50-69 undergoing repeated faecal immunochemical test screening (six rounds) from 2002 to 2015. Test sensitivity was calculated using both the Proportional Interval Cancer Rate and the Interval Cancer Proportion method. Among 441,647 faecal immunochemical tests (123,347 individuals), 150 interval colorectal cancers were detected after a negative faecal immunochemical test. Interval colorectal cancer incidence rate was 1.87 per 10,000 person-years (95%CI: 1.60-2.20), and it was higher during the second interval year (rate ratio: 1.78; 95%CI: 1.28-2.47), for proximal locations (rate ratio: 3.00; 95%CI: 1.92-4.68), and among 60-71 year old subjects (rate ratio: 2.37; 95%CI: 1.61-3.50). The Proportional Interval Cancer Rate was 13.1%, with an overall faecal immunochemical test sensitivity of 86.9% (95%CI: 84.7-89.0). Sensitivity was lowest at the first round (81.5%; 95%CI: 75.6-86.2), and increased to 91.9% (95%CI: 83.9-96.5) for subsequent rounds. Applying the Interval Cancer Proportion method, sensitivity was 83.9% (95%CI: 81.3-86.2), and it was highest at the first round (89.0%; 95%CI: 85.7-91.6), ranging between 73% and 83.1% at subsequent rounds. A faecal immunochemical test sensitivity for cancer higher than 80% resulted in a low incidence of interval colorectal cancers, representing an accurate estimate of one of the major limits of screening programmes. Due to intrinsic biases, the Proportional Interval Cancer Rate and the Interval Cancer Proportion methods generated different trends in faecal immunochemical test sensitivity by screening round.

Identifiants

pubmed: 32393153
doi: 10.1177/0969141320918613
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

131-139

Auteurs

Manuel Zorzi (M)

Veneto Tumour Registry, Azienda Zero, Padova, Italy.

Cesare Hassan (C)

Endoscopy Unit, Nuovo Regina Margherita, Roma, Italy.

Carlo Senore (C)

Centro Prevenzione Oncologica Regione Piemonte and Azienda Ospedaliero-Universitaria S. Giovanni Battista, Torino, Italy.

Giulia Capodaglio (G)

Screening and Health Impact Assessment Unit, Azienda Zero, Padova, Italy.

Anna Turrin (A)

Screening and Health Impact Assessment Unit, Azienda Zero, Padova, Italy.

Elena Narne (E)

Screening and Health Impact Assessment Unit, Azienda Zero, Padova, Italy.

Alessio Mussato (A)

Pathology Unit, Azienda Ospedaliera di Padova, Padova, Italy.

Silvia Rizzato (S)

Veneto Tumour Registry, Azienda Zero, Padova, Italy.

Enrico Chinellato (E)

Veneto Tumour Registry, Azienda Zero, Padova, Italy.

Sara Zamberlan (S)

Veneto Tumour Registry, Azienda Zero, Padova, Italy.

Alessandro Repici (A)

Humanitas University, Rozzano (MI), Italy.

Massimo Rugge (M)

Veneto Tumour Registry, Azienda Zero, Padova, Italy.
Department of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padova, Padova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH